We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04613375
Recruitment Status : Recruiting
First Posted : November 3, 2020
Last Update Posted : December 9, 2022
Information provided by (Responsible Party):

Brief Summary:
Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.

Condition or disease Intervention/treatment
Community Acquired Pneumonia (CAP) Diagnostic Test: Urine sample collection Diagnostic Test: Saliva collection

Detailed Description:
PCV13 efficacy for the prevention of vaccine-type community-acquired pneumonia (VT-CAP) and invasive pneumococcal disease (IPD) was established in the Community-acquired Pneumonia Immunization Trial in Adults (CAPITA) aged 65 and older. However, there are still few available real-life effectiveness estimates in adults. The aim of this study is to evaluate the PCV13 vaccine effectiveness (VE) against hospitalised VT-pneumococcal CAP among adults aged ≥60 years in the Region of Madrid (Spain). Determination of the effectiveness of PCV13 to prevent hospitalised vaccine-type (VT)-pneumococcal CAP among adults aged ≥60 years in Madrid will be evaluated using a test-negative design study, overall and among immunocompetent persons only.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 9000 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Low Intervention Study of the Effectiveness Of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Against Vaccine Type Pneumococcal Hospitalised Community Acquired Pneumonia (CAP) in Adults 60 Years and Older Using A Test Negative Design Study in A Well-Defined Area of the South of Madrid Region
Actual Study Start Date : March 12, 2021
Estimated Primary Completion Date : March 11, 2025
Estimated Study Completion Date : March 11, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Group/Cohort Intervention/treatment
All participants Diagnostic Test: Urine sample collection
Serotype specific UAD (urinary antigen detection) test

Diagnostic Test: Saliva collection
Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR

Primary Outcome Measures :
  1. Vaccine effectiveness (VE) [ Time Frame: 4 years ]
    VE calculated as 1 minus the OR* comparing the odds of having received PCV13 for cases and controls, multiplied by 100, overall and restricted to immunocompetent subjects only.

Secondary Outcome Measures :
  1. Proportion of CAP events for each pneumococcal serotype, PCV-13, and 20-valent pneumococcal conjugate vaccine (PCV20) serotypes among all CAP subjects with UAD1/2 testing (overall) and among all CAP subjects with a pneumococcus identified [ Time Frame: 4 years ]
    Distribution of S. pneumoniae serotypes using blood, high-quality respiratory cultures, and a serotype-specific urinary antigen detection (UAD) assay among adults 60 years of age and older with CAP.

  2. Proportion of persons with respiratory pneumococcal carriage among adults 60 years of age and older presenting with CAP [ Time Frame: 4 years ]
    Proportion of CAP events where the pneumococcus was identified from saliva by the conventional culture or the sensitive molecular method of PCR divided by all CAP events where the subject had a valid saliva specimen test result.

  3. Proportion of participants with CAP and SP-CAP with underlying medical conditions [ Time Frame: 4 years ]
    Proportion of CAP subjects with underlying at-risk and high-risk medical conditions, overall and restricted to those with pneumococcus isolated from blood, high-quality respiratory cultures, and a serotype specific urinary antigen detection (UAD) assay

  4. Frequency of antibiotic resistance among Streptococcus pneumoniae isolates by type [ Time Frame: 4 years ]
    Proportion of S. pneumoniae isolates with antibiotic resistance identified by standard of care testing, overall and by resistance type

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults, aged 60 years and over, who are hospitalized with CAP in one of the study hospitals: Hospital Universitario de Móstoles, Hospital Universitario Fundación de Alcorcón, and Hospital Rey Juan Carlos de Móstoles.

Inclusion Criteria:

  1. Age ≥60 years.
  2. Evidence of pneumonia within first 48 hours of hospital admission
  3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

  1. Any patient who develops signs and symptoms of pneumonia after being hospitalized for ≥48 hours (either at current hospital, another transferring hospital, or a combination of these).
  2. Previously enrolled subjects readmitted ≤14 days after discharge for their study qualifying admission.
  3. At the time of enrollment, pneumonia has been excluded as the diagnosis or another diagnosis confirmed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04613375

Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Layout table for location information
Hospital Universitarios De Getafe Recruiting
Getafe, Madrid, Spain, 28905
Hospital Universitario Severo Ochoa Recruiting
Leganés, Madrid, Spain, 28911
Hospital Universitario de Mostoles Recruiting
Mostoles, Madrid, Spain, 28935
Hospital Universitario Fundación Alcorcón Recruiting
Alcorcón, Madrid, Spain, 28922
Hospital Universitario de Móstoles / Servicio de Oncología Médica Recruiting
Mostoles, Spain, 28935
Hospital Universitario Rey Juan carlos Recruiting
Móstoles, Spain, 28933
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04613375    
Other Study ID Numbers: B1851202
CIBELES ( Other Identifier: Alias Study Number )
First Posted: November 3, 2020    Key Record Dates
Last Update Posted: December 9, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Lung Diseases
Respiratory Tract Diseases